- Home
- MFIN vs CRGX Comparison
MFIN vs CRGX Comparison
Compare MFIN & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFIN
- CRGX
- Stock Information
- Founded
- MFIN 1995
- CRGX 2021
- Country
- MFIN United States
- CRGX United States
- Employees
- MFIN N/A
- CRGX N/A
- Industry
- MFIN Finance: Consumer Services
- CRGX
- Sector
- MFIN Finance
- CRGX
- Exchange
- MFIN Nasdaq
- CRGX Nasdaq
- Market Cap
- MFIN 224.2M
- CRGX 190.0M
- IPO Year
- MFIN 1996
- CRGX 2023
- Fundamental
- Price
- MFIN $8.98
- CRGX $4.27
- Analyst Decision
- MFIN
- CRGX Hold
- Analyst Count
- MFIN 0
- CRGX 7
- Target Price
- MFIN N/A
- CRGX $4.67
- AVG Volume (30 Days)
- MFIN 43.4K
- CRGX 663.4K
- Earning Date
- MFIN 07-29-2025
- CRGX 08-11-2025
- Dividend Yield
- MFIN 3.65%
- CRGX N/A
- EPS Growth
- MFIN N/A
- CRGX N/A
- EPS
- MFIN 1.60
- CRGX N/A
- Revenue
- MFIN $316,751,000.00
- CRGX N/A
- Revenue This Year
- MFIN N/A
- CRGX $58.18
- Revenue Next Year
- MFIN $5.24
- CRGX N/A
- P/E Ratio
- MFIN $5.61
- CRGX N/A
- Revenue Growth
- MFIN 13.91
- CRGX N/A
- 52 Week Low
- MFIN $6.48
- CRGX $3.00
- 52 Week High
- MFIN $10.50
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- MFIN 43.41
- CRGX 45.02
- Support Level
- MFIN $9.08
- CRGX $4.33
- Resistance Level
- MFIN $9.49
- CRGX $4.48
- Average True Range (ATR)
- MFIN 0.27
- CRGX 0.19
- MACD
- MFIN -0.07
- CRGX -0.02
- Stochastic Oscillator
- MFIN 24.21
- CRGX 21.14
About MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. The five operating segments are, (1) recreation, (2) home improvement, (3) commercial, (4) taxi medallion, and (5) strategic partnership loans. The company generates maximum revenue from the Recreation segment.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.